MediciNova Inc. (MNOV)
-NasdaqGM 3.51 
0.33(8.54%) 3:26PM EDT - Nasdaq Real Time Price
| Prev Close: | 3.84 |
|---|
| Open: | 3.63 |
|---|
| Bid: | 3.61 x 300 |
|---|
| Ask: | 3.63 x 200 |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | 1.24 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.45 - 3.77 |
|---|
| 52wk Range: | 1.29 - 4.11 |
|---|
| Volume: | 114,529 |
|---|
| Avg Vol (3m): | 157,862 |
|---|
| Market Cap: | 66.04M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.66 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- MedicNova enters into 6M equity distribution agreement with Macquarieat theflyonthewall.com(Thu, Apr 18)
- MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Wed, Apr 17)
- MEDICINOVA INC Files SEC form 8-K, Other EventsEDGAR Online(Wed, Apr 17)
- MEDICINOVA INC FinancialsEDGAR Online Financials(Wed, Apr 3)
- MEDICINOVA INC Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Fri, Mar 29)
- MediciNova Reports Fourth Quarter and Full Year 2012 ResultsGlobeNewswire(Thu, Mar 28)
- MEDICINOVA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, Mar 28)
- MEDICINOVA INC Files SEC form 10-K, Annual ReportEDGAR Online(Thu, Mar 28)
- MediciNova Announces MN-166 (ibudilast) Opioid Withdrawal and Analgesia Data Presentation at the American Academy of Neurology Annual MeetingGlobeNewswire(Wed, Mar 20)
- 5 of Last Week's Biggest Winnersat Motley Fool(Sun, Mar 3)
- MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Fri, Mar 1)
- Secretive Dilution And A Possible Equity Financing From MediciNovaat Seeking Alpha(Wed, Feb 27)
- Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year HighMarketwired(Wed, Feb 27)
- 4 Healthcare Stock Stories to Heal the Tuesday Bluesat Wall St. Cheat Sheet(Tue, Feb 26)
- FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Methamphetamine DependenceGlobeNewswire(Mon, Feb 25)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 87.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.54 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | -0.26 |
|---|
Business Summary
MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market.
View More